Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) presented data from its Phase 1 trial of soquelitinib for moderate-to-severe atopic dermatitis at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA